Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ADG116 |
Trade Name | |
Synonyms | ADG-116|ADG 116|Firastotug |
Drug Descriptions |
ADG116 is a monoclonal antibody that targets CTLA4, which potentially induces antitumor activity (Journal for ImmunoTherapy of Cancer 2022;10). |
DrugClasses | CTLA4 Antibody 32 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | 2750031-14-0 |
NCIT ID | C166139 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ADG106 + ADG116 | ADG106 ADG116 | 0 | 1 |
ADG116 | ADG116 | 0 | 2 |
ADG116 + Pembrolizumab | ADG116 Pembrolizumab | 0 | 1 |
ADG116 + unspecified PD-1 antibody | ADG116 unspecified PD-1 antibody | 0 | 1 |